Medicus Pharma (MDCX) Consolidated Net Income (2024 - 2025)
Medicus Pharma (MDCX) posted Consolidated Net Income of -$7.8 million for Q4 2025, down 51937233.33% quarter-over-quarter from -$15.0 in Q3 2025, and down 117.28% year-on-year from $45.1 million in Q4 2024.
Medicus Pharma (MDCX) Consolidated Net Income (2024 - 2025) Analysis & Trends
Medicus Pharma (MDCX) has reported Consolidated Net Income for 2 consecutive years, with -$7.8 million the latest figure, recorded in Q4 2025.
- Consolidated Net Income for Q4 2025 came in at -$7.8 million, down 117.28% year-over-year; the trailing twelve-month figure through Dec 2025 was -$18.9 million (down 69.12% YoY), and the FY2025 annual result was -$34.4 million, down 208.0% from the prior year.
- Consolidated Net Income was -$7.8 million for Q4 2025 at Medicus Pharma, down from -$15.0 in the prior quarter.
- Over five years, Consolidated Net Income peaked at -$15.0 in Q3 2025 and troughed at -$7.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.40 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 5.24 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 697.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 833.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -13.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Medicus Pharma | 6.91 Mn | -1.69 Mn | - | -7.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.79 Mn |
| Sep 30, 2025 | -15.00 |
| Jun 30, 2025 | -6.02 Mn |
| Mar 31, 2025 | -5.10 Mn |
| Dec 31, 2024 | -3.59 Mn |
| Sep 30, 2024 | -2.33 Mn |
| Jun 30, 2024 | -3.55 Mn |
| Mar 31, 2024 | -1.71 Mn |